Mylan Laboratories Limited — Glimepiride Exporter Profile
Indian Pharmaceutical Exporter · #8 for Glimepiride · $1.3M export value · DGFT Verified
Mylan Laboratories Limited is the #8 Indian exporter of Glimepiride with $1.3M in export value and 86 verified shipments. Mylan Laboratories Limited holds a 1.7% market share in Glimepiride exports across 4 countries. The company exports 91 pharmaceutical products worth $634.8M across 26 therapeutic categories.
Mylan Laboratories Limited — Glimepiride Export Profile: Buyers & Destinations
Where Does Mylan Laboratories Limited Export Glimepiride?
| Country | Value | Shipments | Share |
|---|---|---|---|
| HUNGARY | $475.5K | 20 | 38.1% |
| FRANCE | $413.4K | 36 | 33.1% |
| NETHERLANDS | $336.0K | 19 | 26.9% |
| SPAIN | $23.8K | 11 | 1.9% |
Mylan Laboratories Limited exports Glimepiride to 4 countries. The largest destination is HUNGARY accounting for 38.1% of Mylan Laboratories Limited's Glimepiride shipments, followed by FRANCE (33.1%) and NETHERLANDS (26.9%). These destinations reflect Mylan Laboratories Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Glimepiride from Mylan Laboratories Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| MYLAN HUNGARY KFT, | HUNGARY | $217.5K | 10 |
| MYLAN IRELAND C/O ALLOGA RDC, | NETHERLANDS | $217.2K | 14 |
| MYLAN HUNGARY KFT MYLAN U | HUNGARY | $174.1K | 7 |
| CSP | FRANCE | $109.4K | 5 |
| CSP VIATRIS SANTE AT CSP-LAB | FRANCE | $95.5K | 15 |
| MYLAN IRELAND C O ALLOGA RDC | NETHERLANDS | $92.5K | 3 |
| MYLAN HUNGARY KFT | HUNGARY | $73.1K | 2 |
| CSP VIATRIS SANTE AT CSP- LAB, | FRANCE | $55.9K | 5 |
| CSP VIATRIS SANT? AT CSP- LAB | FRANCE | $53.5K | 3 |
| CSP VIATRIS SANTE AT CSP- LABO, | FRANCE | $48.3K | 2 |
Mylan Laboratories Limited supplies Glimepiride to 18 buyers globally. The largest buyer is MYLAN HUNGARY KFT, (HUNGARY), followed by MYLAN IRELAND C/O ALLOGA RDC, (NETHERLANDS) and MYLAN HUNGARY KFT MYLAN U (HUNGARY). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Glimepiride Export Value and How Much Does Mylan Laboratories Limited Contribute?
India exported $23.4M worth of Glimepiride through 3,159 shipments from 242 suppliers to 94 countries, serving 535 buyers globally. Mylan Laboratories Limited contributes $1.3M to this total, accounting for 1.7% of India's Glimepiride exports. Mylan Laboratories Limited ships Glimepiride to 4 countries through 18 buyers.
What Is the Average Shipment Value for Mylan Laboratories Limited's Glimepiride Exports?
Mylan Laboratories Limited's average Glimepiride shipment value is $14.8K per consignment, based on 86 shipments totaling $1.3M. The largest destination is HUNGARY (38.1% of Mylan Laboratories Limited's Glimepiride exports).
How Does Mylan Laboratories Limited Compare to Other Indian Glimepiride Exporters?
Mylan Laboratories Limited ranks #8 among 242 Indian Glimepiride exporters with a 1.7% market share. The top 3 exporters are MICRO LABS LIMITED ($5.3M), IPCA LABORATORIES LIMITED ($3.6M), INVENTIA HEALTHCARE LIMITED ($3.0M). Mylan Laboratories Limited processed 86 shipments to 4 destination countries.
What Glimepiride Formulations Does Mylan Laboratories Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| GLIMEPIRIDE TAB 4MG EU PACKS 8000S BSP | $92.8K | 4 |
| GLIMEPIRIDE TABLETS 2 MG | $68.2K | 2 |
| GLIMEPIRIDE TABLETS 3 MG | $66.1K | 2 |
| GLIMEPIRIDE TAB 3MG 90BL CZ MY Packs 6X15 S BLISTER Packs 17245 000 X6X15 1552050 00 NOS | $62.1K | 2 |
| GLIMEPIRIDE TABLETS 3 MG PACKS 8000S | $50.0K | 1 |
| HARMLESS MEDICINES, GLIMEPIRIDE TAB 2MG90BL CZ MY (31065 PACKS) | $46.3K | 1 |
| GLIMEPIRIDE TAB 3MG 90BL CZ MY PACKS 10414 | $38.9K | 2 |
| HARMLESS MEDICINES:- GLIMEPIRIDE TABLETS2 MG PACK:3467600.000 | $34.5K | 1 |
| HARMLESS MEDICINES:- GLIMEPIRIDE TABLETS3 MG PACK:2337450.000 | $34.0K | 1 |
| GLIMEPIRIDE TABLETS 4 MG | $31.4K | 1 |
Mylan Laboratories Limited exports 61 distinct Glimepiride formulations including tablets, capsules, syrups, and combination drugs. The top formulation is GLIMEPIRIDE TAB 4MG EU PACKS 8000S BSP with 4 shipments worth $92.8K.
How Does Mylan Laboratories Limited Compare to Nearest Glimepiride Exporters?
Exporters ranked immediately above and below #8 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 1 | INDOCO REMEDIES LIMITED | $2.0M | 41 | 2 | $50.0K |
| 6 | SUN PHARMACEUTICAL INDUSTRIES LIMITED | $1.6M | 66 | 4 | $23.6K |
| 8 | MYLAN LABORATORIES LIMITED ★ | $1.3M | 86 | 4 | $14.8K |
| 9 | AJANTA PHARMA LIMITED | $1.2M | 41 | 3 | $28.4K |
| 10 | AUROBINDO PHARMA LTD | $882.8K | 203 | 3 | $4.3K |
Mylan Laboratories Limited ranks #8 among 242 Indian Glimepiride exporters. Average shipment value of $14.8K compared to the market average of $96.6K. The closest competitors by value are INDOCO REMEDIES LIMITED and SUN PHARMACEUTICAL INDUSTRIES LIMITED.
Which Indian Ports Ship Glimepiride Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR | 350 | 11.1% |
| NHAVA SHEVA SEA (INNSA1) | 268 | 8.5% |
| SAHAR AIR CARGO ACC (INBOM4) | 241 | 7.6% |
| DELHI AIR CARGO ACC (INDEL4) | 228 | 7.2% |
| DELHI AIR | 226 | 7.2% |
| JNPT/ NHAVA SHEVA SEA | 172 | 5.4% |
| BANGALORE ACC (INBLR4) | 148 | 4.7% |
| BANGALORE AIR | 110 | 3.5% |
Geopolitical & Trade Policy Impact on Mylan Laboratories Limited's Glimepiride Exports
Mylan's export operations are influenced by a complex geopolitical landscape. The Israel-Iran tensions have led to disruptions in Red Sea shipping routes, resulting in increased freight costs and extended transit times. Major shipping lines have implemented 'Emergency Risk Surcharges' ranging from $250 to $500 per TEU, directly impacting the cost structure for Indian pharmaceutical exporters like Mylan. Additionally, diversions around the Cape of Good Hope have further elongated delivery schedules, posing challenges to time-sensitive pharmaceutical shipments.
In the United States, the imposition of tariffs on pharmaceutical imports has prompted Indian companies to reassess their market strategies. While generics have largely remained exempt, the potential for future tariff expansions necessitates vigilance. Mylan, along with other Indian exporters, is exploring market diversification to mitigate reliance on the U.S. market. The recent India-European Union Free Trade Agreement (FTA), signed in January 2026, offers a strategic avenue for expansion. The FTA eliminates tariffs on approximately 97% of EU tariff lines, including pharmaceuticals, thereby enhancing market access for Indian exporters. This agreement is expected to significantly boost India's pharmaceutical exports to Europe, providing a counterbalance to uncertainties in the U.S. market.
Mylan Laboratories Limited — Regulatory Compliance & Quality Standards
Compliance with international regulatory standards remains paramount for Mylan. The FDA's warning letter and import alert in December 2024 concerning the Indore facility underscore the critical importance of stringent quality control measures. The cited violations, including subpar quality control and improper management of manufacturing defects, have necessitated comprehensive corrective actions. Mylan's proactive response aims to restore compliance and reinforce its commitment to quality assurance.
The evolving regulatory environment, particularly in the European Union, further emphasizes the need for adherence to Good Manufacturing Practices (GMP). The EU's Falsified Medicines Directive mandates rigorous compliance to ensure product integrity and patient safety. For Mylan, aligning with these standards is essential to maintain and expand its foothold in the European market.
About Mylan Laboratories Limited
Mylan Laboratories Limited exports 91 products worth $634.8M. Beyond Glimepiride, top products include Tenofovir, Pantoprazole, Valsartan, Ritonavir, Trastuzumab. View the complete Mylan Laboratories Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Glimepiride — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Glimepiride shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Mylan Laboratories Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 86 individual customs records matching Mylan Laboratories Limited exporting Glimepiride, covering 61 formulations to 4 countries via 18 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 94+ countries, 535+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Glimepiride Export Data from Mylan Laboratories Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Mylan Laboratories Limited's Glimepiride exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Mylan Laboratories Limited
Full Company Profile →
91 products · $634.8M total trade · 26 categories
Glimepiride Stats
Company Overview
Top Products by Mylan Laboratories Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Mylan Laboratories Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Glimepiride. For current shipment-level data, contact TransData Nexus.